6 citations
,
February 2023 in “Journal of the American Academy of Dermatology” Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
105 citations
,
April 2014 in “Trends in Pharmacological Sciences” Targeting the Smoothened receptor shows promise for treating certain cancers.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
13 citations
,
December 2017 in “Archives of Medical Sciences” Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
Suppressing ODC activity reduces tumor growth in hair follicles.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
474 citations
,
January 2012 in “Chemistry & biology” Proteasome inhibitors are promising treatments for various cancers, autoimmune diseases, and other conditions.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” Analog 23 is a promising compound for prostate cancer treatment.
A 12-year-old girl was misdiagnosed with alopecia areata but actually had a nevus sebaceus with a genetic mutation.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
December 2010 in “Cancer Prevention Research” Presurgical models can effectively and affordably screen cancer prevention agents.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
3 citations
,
January 2025 in “SAGE Open Medical Case Reports” Deucravacitinib helped regrow hair and reduce plaques in a woman with discoid lupus erythematosus without side effects.
Finasteride may help treat childhood brain tumors by activating certain genes.
50 citations
,
September 2009 in “Molecular Genetics and Metabolism” A new gene mutation causes vitamin D resistance and rickets, treatable with calcium therapy.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
9 citations
,
March 2016 in “Natural Product Research” Some flavonoids may help with hair growth by affecting blood vessel function in hair follicles.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
Valproic acid and rapamycin protect hair follicle stem cells from damage by activating a protective pathway.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
23 citations
,
December 2004 in “Seminars in oncology” Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
The treatment was ineffective in humans.
2 citations
,
March 2012 in “JAMA” Early surgery reduces seizure risk in drug-resistant epilepsy; testosterone to DHT conversion doesn't affect muscle anabolism; veterans with PTSD likely to have riskier opioid use; bevacizumab helps in hereditary bleeding disorder.
38 citations
,
December 2009 in “Therapeutic Advances in Medical Oncology” The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.